Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOLANA BEACH, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL, OR NEUROLOGICAL CONDITIONS, ANNOUNCES THE PUBLICATION OF A PEER-REVIEWED ARTICLE, THE EMERGING ROLE OF FATTY ACID BINDING PROTEIN 3 (FABP3) IN CANCERS, IN DRUG DISCOVERY TODAY.

ARTELO BIOSCIENCES ANNOUNCES PUBLICATION OF PEER-REVIEWED ARTICLE ON ROLE OF FATTY ACID BINDING PROTEINS IN CANCER

SOLANA BEACH, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ: ARTL), A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGICAL, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE APPOINTMENT OF MARK SPRING, CPA, AS CHIEF FINANCIAL OFFICER, EFFECTIVE NOVEMBER 1, 2025.

ARTELO BIOSCIENCES NAMES VETERAN LIFE SCIENCES EXECUTIVE MARK SPRING, CPA, AS CHIEF FINANCIAL OFFICER

ART26.12 PHASE 1 DATA DEMONSTRATED NO SAFETY CONCERNS, PREDICTABLE LINEAR PLASMA EXPOSURE, AND OPTIONS FOR DOSING IN EITHER FED OR FASTED CONDITIONS ART27.13 INTERIM PHASE 2 DATA SHOWED SUBSTANTIAL WEIGHT GAIN AND ACTIVITY IMPROVEMENTS IN THE TREATED PATIENTS VERSUS PLACEBO SOLANA BEACH, CALIF., OCT. 15, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THAT PROFESSOR SAOIRSE O'SULLIVAN, VICE PRESIDENT OF TRANSLATIONAL SCIENCES AT ARTELO BIOSCIENCES, IS PRESENTING EXPANDED DATA FROM ARTELO'S LEAD FATTY ACID BINDING PROTEIN 5 (FABP5) INHIBITOR, ART26.12, SINGLE ASCENDING DOSE (SAD) STUDY AT THE 8TH ANNUAL CANNABINOID & ENDOCANNABINOID DRUG DEVELOPMENT SUMMIT, TAKING PLACE OCTOBER 1516, 2025, IN BOSTON, MASSACHUSETTS.

ARTELO BIOSCIENCES ANNOUNCES EXPANDED CLINICAL DATA TO BE PRESENTED ON BOTH ART26.12 AND ART27.13 AT THE 8TH ANNUAL CANNABINOID & ENDOCANNABINOID DRUG DEVELOPMENT SUMMIT

SOLANA BEACH, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 441,210 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 13,335 SHARES OF ARTELO'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.399 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ARTELO'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ARTELO BIOSCIENCES ANNOUNCES CLOSING OF $2.0 MILLION PUBLIC OFFERING

SOLANA BEACH, CALIF., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 441,210 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 13,335 SHARES OF ARTELO'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.399 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ARTELO'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ARTELO BIOSCIENCES ANNOUNCES PRICING OF $2.0 MILLION PUBLIC OFFERING

SOLANA BEACH, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK AND/OR PRE-FUNDED WARRANTS. ALL SHARES OF COMMON STOCK AND/OR PRE-FUNDED WARRANTS IN THE OFFERING ARE TO BE OFFERED BY THE COMPANY. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

ARTELO BIOSCIENCES ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING

PATIENTS TREATED WITH ART27.13 SHOWED CONSISTENT IMPROVEMENTS IN WEIGHT, LEAN BODY MASS, AND ACTIVITY WHILE CLINICAL BENEFITS WERE OBSERVED IN ALL TREATED COHORTS, THE BEST OUTCOMES IN CARES WERE OBSERVED IN PATIENTS TITRATED TO THE HIGHEST DOSE SOLANA BEACH, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE FIRST PUBLIC PRESENTATION OF THE INTERIM DATA FROM ITS PHASE 2 CANCER APPETITE RECOVERY STUDY (CARES) EVALUATING ART27.13 IN PATIENTS WITH CANCER ANOREXIA-CACHEXIA SYNDROME (CACS).

ARTELO BIOSCIENCES ANNOUNCES PRESENTATION OF POSITIVE INTERIM PHASE 2 CARES DATA ON ART27.13 AT THE 2025 CANCER CACHEXIA SOCIETY CONFERENCE

SOLANA BEACH, CALIF., SEPT. 05, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 640,924 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 40,894 SHARES OF ARTELO'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.399 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ARTELO'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT.

ARTELO BIOSCIENCES ANNOUNCES CLOSING OF $3.0 MILLION PUBLIC OFFERING

SOLANA BEACH, CALIF., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 640,924 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE UP TO 40,894 SHARES OF ARTELO'S COMMON STOCK AT A PRICE TO THE PUBLIC OF $4.399 PER PRE-FUNDED WARRANT, WHICH REPRESENTS THE PER SHARE PUBLIC OFFERING PRICE OF EACH SHARE OF ARTELO'S COMMON STOCK LESS THE $0.001 PER SHARE EXERCISE PRICE FOR EACH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS FROM THE OFFERING ARE EXPECTED TO BE APPROXIMATELY $3.0 MILLION, PRIOR TO DEDUCTING UNDERWRITING DISCOUNTS AND OTHER OFFERING EXPENSES. IN ADDITION, THE COMPANY HAS GRANTED THE UNDERWRITERS A 45-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 102,272 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LESS THE UNDERWRITING DISCOUNTS TO COVER OVER-ALLOTMENTS, IF ANY. THE OFFERING IS EXPECTED TO CLOSE ON SEPTEMBER 5, 2025, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

ARTELO BIOSCIENCES ANNOUNCES PRICING OF $3.0 MILLION PUBLIC OFFERING

SOLANA BEACH, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) ,A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK AND/OR PRE-FUNDED WARRANTS. ALL SHARES OF COMMON STOCK AND/OR PRE-FUNDED WARRANTS IN THE OFFERING ARE TO BE OFFERED BY THE COMPANY. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

SOLANA BEACH, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, AFFIRMS THAT, BASED ON THE STRENGTH OF THE POSITIVE INTERIM RESULTS FROM ITS PHASE 2 CARES TRIAL OF ART27.13 FOR CANCER ANOREXIA-CACHEXIA SYNDROME (CACS) AND THE STRONG INTEREST EXPRESSED BY MULTIPLE PHARMACEUTICAL COMPANIES AWAITING THESE RESULTS, IT IS WELL POSITIONED TO SECURE A DEVELOPMENT PARTNER FOR ART27.13. CACS, A LEADING CAUSE OF DEATH IN CANCER PATIENTS AND AFFECTING UP TO 80% OF THOSE LIVING WITH CANCER, CURRENTLY HAS NO FDA-APPROVED TREATMENT.

ARTELO BIOSCIENCES AFFIRMS STRONG PARTNERING OUTLOOK FOR ART27.13 FOLLOWING POSITIVE INTERIM PHASE 2 CARES RESULTS

CATALYST FOR ADVANCING DISCUSSIONS WITH PHARMACEUTICAL COMPANIES THAT HAVE EXPRESSED INTEREST IN ART27.13 FOR CACS CONSISTENT IMPROVEMENTS IN WEIGHT GAIN, LEAN BODY MASS, AND ACTIVITY WERE OBSERVED ACROSS TREATED PATIENTS INCLUDING +6.4% MEAN WEIGHT GAIN AT 12 WEEKS VS 5.4% MEAN WEIGHT LOSS ON PLACEBO SAFETY RESULTS SHOWED ART27.13 WAS WELL TOLERATED SOLANA BEACH, CALIF., SEPT. 03, 2025 (GLOBE NEWSWIRE) -- ARTELO BIOSCIENCES, INC. (NASDAQ:ARTL) , A CLINICAL-STAGE PHARMACEUTICAL COMPANY FOCUSED ON MODULATING LIPID-SIGNALING PATHWAYS TO DEVELOP TREATMENTS FOR PEOPLE LIVING WITH CANCER, PAIN, DERMATOLOGIC, OR NEUROLOGICAL CONDITIONS, TODAY ANNOUNCED HIGHLY ENCOURAGING INTERIM RESULTS FROM ITS PHASE 2 CANCER APPETITE RECOVERY STUDY (CARES) TRIAL WITH ART27.13, THE COMPANY'S PERIPHERALLY ACTING CANNABINOID RECEPTOR AGONIST FOR THE TREATMENT OF CANCER ANOREXIA-CACHEXIA SYNDROME (CACS).

Artelo Biosciences, Inc.

ARTL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Artelo Biosciences, Inc.

ARTL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ARTL